New trial aims to boost survival in recurrent nasopharyngeal cancer with surgery and drug combo
NCT ID NCT07129772
Summary
This study is testing a combination treatment for people whose nasopharyngeal cancer has come back in the original area. Participants will receive a drug (pembrolizumab) and chemotherapy before surgery to remove the tumor, followed by more of the drug after surgery. The goal is to see if this approach can better control the cancer and improve survival compared to current options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Clinical Oncology, Queen Mary Hospital
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.